Company Scales Multi-Omics Diagnostics via Mayo Clinic Partnership and Lumee Monitoring
- (Nasdaq: PFSA) announced on April 6, 2026, a strategic expansion into the molecular diagnostics market through a letter of intent to acquire the PanOmics multi-omics diagnostics platform from...
- The transaction is valued at $30 million and is expected to add $30 million of shareholder equity to the balance sheet of the Berkeley, California-based digital health company.
- In conjunction with the acquisition, Profusa launched a partnership with the Mayo Clinic.
Profusa, Inc. (Nasdaq: PFSA) announced on April 6, 2026, a strategic expansion into the molecular diagnostics market through a letter of intent to acquire the PanOmics multi-omics diagnostics platform from BioInsights LLC.
The transaction is valued at $30 million and is expected to add $30 million of shareholder equity to the balance sheet of the Berkeley, California-based digital health company.
In conjunction with the acquisition, Profusa launched a partnership with the Mayo Clinic. This collaboration is designed to advance the application of the company’s technology in addressing the unmet needs of pancreatic cancer.
The PanOmics platform will complement Profusa’s existing Lumee real-time biochemistry monitoring platform. The company stated that this combination is intended to position the firm at the intersection of biosensing, diagnostics, and precision medicine, creating a foundation for a scalable multi-product diagnostics and monitoring franchise.
This is a pivotal step in the evolution of Profusa. The combination of the PanOmics platform and our collaboration with Mayo Clinic positions us to build a differentiated, scalable presence in precision diagnostics and surgical monitoring.
Dr. Ben Hwang, Profusa Chairman and Chief Executive Officer
According to Dr. Ben Hwang, the company’s entry into the field of pancreatic cancer is instrumental for establishing a platform that can support multiple indications and facilitate long-term growth.
Profusa intends to leverage the Mayo Clinic’s status as a leading medical institution to gain access to clinical samples and a clear validation pathway. The company believes these factors will allow it to accelerate development, increase clinical adoption, and unlock commercial value.
With access to clinical samples, a clear validation pathway, and our previously announced collaboration with the Mayo Clinic, one of the world’s leading medical institutions, we believe we are uniquely positioned to accelerate development, drive clinical adoption, and unlock meaningful near-term high-growth commercial value.
Dr. Ben Hwang, Profusa Chairman and Chief Executive Officer